Parkinson’s Disease

Dysarthria and cognitive changes are cardinal symptoms of PD. We can reliably measure motor and linguistic deficits as indicators of brain health and quality of life in this condition.

Objectively measure speech in Parkinson’s disease patients with great precision

u003cpu003eIn 2020, an estimatedu0026nbsp;u003cstrongu003e9.4 millionu003c/strongu003eu0026nbsp;people globally were living with Parkinsonu0026rsquo;s disease, with numbers increasing tou0026nbsp;u003cstrongu003e12.7 millionu003c/strongu003eu0026nbsp;people by 2027. Coupled with the subjective nature of current Parkinsonu0026rsquo;s disease monitoring assessment methods, there is a need for sensitive, scalable and meaningful assessments of disease monitoring. Redenlab is a world leader in the development of speech data capture and analysis tools, creating objective motor speech and cognitive-linguistic-based assessments. Their approach has proven utility in industry and academic driven studies, enhancing decision making at each stage of the drug development and evaluation process.u003c/pu003e

A man in a dress shirt and suspenders holding a tablet

How Redenlab does it better

Easy transition to objective assessment

Redenlab offers custom protocols and assessment strategies alongside their data capture and analysis tools. Testing is easy to use, and outcomes make sense to clinicians, patients and regulators.

Purpose built algorithms

Different treatments provide different therapeutic outcomes. Redenlab builds your algorithm from the ground up to ensure your data yield the most sensitive and meaningful outcomes for tracking change in performance

Clinically motivated metrics with cutting edge technology

Redenlab scientists are experts in clinical speech science. Their technology team bring expertise in data capture and analysis. Together these strengths ensure your trial is grounded in the best patient focussed outcomes as well as sophisticated signal processing and data analytics.

ParkinSong: a clinical trial turn PD treatment

u003cpu003eWorking with scientists from the Conservatorium of Music at The University of Melbourne in Australia, Redenlab assisted in outcome measure design and analysis for a randomized trial of ParkinSong, a group therapy session for people with Parkinsonu0026rsquo;s disease.u003c/pu003eu003cpu003eSince its clinical trial, the therapy has been employed across Australia byu0026nbsp;u003cstrongu003eParkinsonu0026rsquo;s Australiau003c/strongu003e, an Australian advocacy group dedicated to improving the quality of life of people diagnosed with Parkinsonu0026rsquo;s disease.u003c/pu003e